

## Sanofi launches SOLIQUA in Singapore to treat adults with uncontrolled T2D

14 November 2019 | News

Administered once-daily, SOLIQUA® allows patients with uncontrolled type 2 diabetes take charge of their longterm health



Sanofi on 13 Nov 2019, announced the launch of SOLIQUA<sup>®</sup>, its once-daily injectable treatment which aims to relieve the burden of uncontrolled type 2 diabetes (T2D) in Singapore in a simple, single step.

Uncontrolled diabetes is a growing threat and occurs when the blood sugar level of a patient with type 2 diabetes is above the recommended target range set by their doctor. It is reported in as many as half of patients with type 2 diabetes who are using medication. This may be due to factors such as the severity of the condition, non-adherence to lifestyle changes or the complex regimens of treatment required by patients, which may include multiple injections throughout the day

Dr Khoo Chin Meng (Head & Senior Consultant, Division of Endocrinology, University Medicine Cluster, National University Hospital) said, "Long-standing type 2 diabetes mellitus and poorly controlled diabetes lead to many complications such as kidney damage, eye damage and blindness, loss of peripheral sensation, heart disease and stroke. The key thrust in the War on Diabetes is prevention; preventing diabetes from happening and preventing complications among those with diabetes. Lifestyle changes which include diet, physical activity and smoking cessation are critical to long term management of diabetes. It is also important to educate patients on various treatment options available to control diabetes, obesity and other cardiovascular risk factors."

SOLIQUA<sup>®</sup> is the first-of-its-kind treatment in Singapore that is indicated in combination with metformin for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control when this has not been provided by metformin alone, metformin combined with another oral glucose-lowering medicinal product or with basal insulin. Its fixed-ratio combination of basal insulin glargine (100 Units/mL) and GLP-1 RA lixisenatide as a complementary mode of action, working to keep blood sugar within target levels.

Dr Ben Ng (Endocrinologist, ARDEN Endocrinology Specialist Clinic, Mount Elizabeth Novena Specialist Centre, Mount Elizabeth Medical Centre) said, "As a once-daily treatment, SOLIQUA® could benefit patients who have difficulty keeping up with their diabetes management plan, given the hectic lifestyles of everyday Singaporeans. The ease of use of this innovative yet effective treatment allows patients to have better control of blood sugar levels."

SOLIQUA® was evaluated in a Phase II proof-of-concept study and two pivotal Phase III clinical trials: LixiLan-L and LixiLan-O. In these studies, SOLIQUA® demonstrated greater reductions in blood sugar levels compared with its individual components and showed a favourable safety profile, with a lower risk of weight gain and no increased risk of hypoglycaemia, compared to basal insulin (Lantus).

Dr Shiva Patil (Medical Head, Thailand, Malaysia and Singapore, Sanofi-Aventis Singapore) said, "At Sanofi, we have been committed to developing diabetes solutions for close to a century. SOLIQUA® is a unique combination of basal insulin (glargine) and GLP-1 RA, lixisenatide, that has been approved for adults with uncontrolled type 2 diabetes. This fixed-ratio combination (FRC) provides effective control on the fasting and postprandial glucose levels, thus helping help more patients achieve their treatment goals while mitigating weight gain and hypoglycemia associated with insulin therapy, and gastrointestinal side-effects with GLP-1RAs. Based on the evidence, this FRC can provide effective HbA1c control for patients uncontrolled on either oral drugs or injectables such as basal insulin."